SIMVASTATIN-INDUCED RHABDOMYOLYSIS IN A HEART-TRANSPLANT RECIPIENT RECEIVING CYCLOSPORINE

被引：14

作者：

BLAISON, G ^{[1
]}

WEBER, JC ^{[1
]}

SACHS, D ^{[1
]}

KORGANOW, AS ^{[1
]}

MARTIN, T ^{[1
]}

KRETZ, JG ^{[1
]}

PASQUALI, JL ^{[1
]}

机构：

[1] CHU STRASBOURG,SERV MED INTERNE A,UNITE IMMUNOPATHOL,F-67091 STRASBOURG,FRANCE

来源：

REVUE DE MEDECINE INTERNE | 1992年 / 13卷 / 01期

关键词：

RHABDOMYOLYSIS; UNDESIRABLE DRUG EFFECTS; HEART TRANSPLANTATION; SIMVASTATIN;

D O I：

10.1016/S0248-8663(05)80013-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are cholesterol-lowering agents which may induce rhabdomyolysis. The authors present a case of rhabdomyolysis attributed to simvastatin in a heart-transplant recipient. They stress the probability of a dose-dependent muscular toxicity and the risk of overdosage in patients already under treatment with drugs that interfere with the pharmacokinetics of HMG-CoA reductase inhibitors, notably ciclosporine.

引用

页码：61 / 63

页数：3